More than 100 million people worldwide suffer from a retinal disease that threatens their eyesight. A13-billion-dollar drug can prevent the loss of visual acuity. Nevertheless, two thirds of cases of blindness in the EU and USA are due to these diseases particularly wet age-related macular degeneration (AMD). deepeye offers an AI-based precision medicine platform that aims to improve therapy outcomes by up to 6 times by:
deepeye’s vision is to save an additional 1 million people from blindness by 2030 by enabling ophthalmologists to “look into the future of their patients” and obtain an optimal therapy prognosis with the help of AI. deepeye’s AI is already being used for research purposes by Novartis, Bayer, Roche and medical associations to gain new insights into their therapy data. Thanks to other partners such as Heidelberg Engineering and Topcon Healthcare, the therapy decision aid will soon be available at the point of care with just one click.
